Update on cytokines in rheumatoid arthritis

Brennan, 1996, Cytokines in autoimmunity, Curr Opin Immunol, 8, 872, 10.1016/S0952-7915(96)80018-5

Feldmann, 1996, Role of cytokines in rheumatoid arthritis, Annu Rev Immunol, 14, 397, 10.1146/annurev.immunol.14.1.397

Olsen, 2004, A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells, Ann Rheum Dis, 63, 1387, 10.1136/ard.2003.017194

Bovin, 2004, Blood cell gene expression profiling in rheumatoid arthritis. Discriminative genes and effect of rheumatoid factor, Immunol Lett, 93, 217, 10.1016/j.imlet.2004.03.018

van der Pouw Kraan, 2003, Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair, Genes Immun, 4, 187, 10.1038/sj.gene.6363975

Tsubaki, 2005, Characterization of histopathology and gene-expression profiles of synovitis in early rheumatoid arthritis using targeted biopsy specimens, Arthritis Res Ther, 7, R825, 10.1186/ar1751

Baechler, 2003, Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus, Proc Natl Acad Sci USA, 100, 2610, 10.1073/pnas.0337679100

Bennett, 2003, Interferon and granulopoiesis signatures in systemic lupus erythematosus blood, J Exp Med, 197, 711, 10.1084/jem.20021553

Kirou, 2004, Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus, Arthritis Rheum, 50, 3958, 10.1002/art.20798

Kirou, 2005, Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease, Arthritis Rheum, 52, 1491, 10.1002/art.21031

de Jager, 2005, Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies, J Immunol Meth, 300, 124, 10.1016/j.jim.2005.03.009

de Jager, 2003, Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells, Clin Diagn Lab Immunol, 10, 133, 10.1128/CDLI.10.1.133-139.2003

Raza, 2005, Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin, Arthritis Res Ther, 7, R784, 10.1186/ar1733

Hueber, 2005, Antigen microarray profiling of autoantibodies in rheumatoid arthritis, Arthritis Rheum, 52, 2645, 10.1002/art.21269

Weaver, 2006, Th17: an effector CD4 T cell lineage with regulatory T cell ties, Immunity, 24, 677, 10.1016/j.immuni.2006.06.002

Nakae, 2003, Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice, J Immunol, 171, 6173, 10.4049/jimmunol.171.11.6173

Stamp, 2004, Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis?, Immunol Cell Biol, 82, 1, 10.1111/j.1440-1711.2004.01212.x

Bush, 2002, Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein, Arthritis Rheum, 46, 802, 10.1002/art.10173

Lubberts, 2004, Treatment with a neutralizing antimurine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion, Arthritis Rheum, 50, 650, 10.1002/art.20001

Koenders, 2006, Interleukin-17 acts independently of TNF-alpha under arthritic conditions, J Immunol, 176, 6262, 10.4049/jimmunol.176.10.6262

Rohn, 2006, Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis, Eur J Immunol, 36, 2857, 10.1002/eji.200636658

Chabaud, 1999, Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium, Arthritis Rheum, 42, 963, 10.1002/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E

Kotake, 1999, IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis, J Clin Invest, 103, 1345, 10.1172/JCI5703

Kirkham, 2006, Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort), Arthritis Rheum, 54, 1122, 10.1002/art.21749

Wraith, 2006, Anticytokine vaccines and the immunotherapy of autoimmune diseases, Eur J Immunol, 36, 2844, 10.1002/eji.200636760

Oppmann, 2000, Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12, Immunity, 13, 715, 10.1016/S1074-7613(00)00070-4

Parham, 2002, A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R, J Immunol, 168, 5699, 10.4049/jimmunol.168.11.5699

Murphy, 2003, Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation, J Exp Med, 198, 1951, 10.1084/jem.20030896

Iwakura, 2006, The IL-23/IL-17 axis in inflammation, J Clin Invest, 116, 1218, 10.1172/JCI28508

Chen, 2006, Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis, J Clin Invest, 116, 1317, 10.1172/JCI25308

Veldhoen, 2006, TGFβ1, a ‘Jack of all trades’: the link with pro-inflammatory IL-17-producing T cells, Trends Immunol, 27, 358, 10.1016/j.it.2006.06.001

Veldhoen, 2006, TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells, Immunity, 24, 179, 10.1016/j.immuni.2006.01.001

Hirano, 1988, Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis, Eur J Immunol, 18, 1797, 10.1002/eji.1830181122

Brennan, 1990, Detection of transforming growth factor-β in rheumatoid arthritis synovial tissue: lack of effect on spontaneous cytokine production in joint cell cultures, Clin Exp Immunol, 81, 278, 10.1111/j.1365-2249.1990.tb03331.x

Wada, 2007, Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor, Blood, 109, 1156, 10.1182/blood-2006-04-019398

Wei, 2006, IL-20: biological functions and clinical implications, J Biomed Sci, 13, 601, 10.1007/s11373-006-9087-5

Moore, 1993, Interleukin-10, Annu Rev Immunol, 11, 165, 10.1146/annurev.iy.11.040193.001121

Katsikis, 1994, Immunoregulatory role of interleukin 10 in rheumatoid arthritis, J Exp Med, 179, 1517, 10.1084/jem.179.5.1517

Hsu, 2006, Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis, Arthritis Rheum, 54, 2722, 10.1002/art.22039

Ikeuchi, 2005, Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine, Arthritis Rheum, 52, 1037, 10.1002/art.20965

Liang, 2006, Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides, J Exp Med, 203, 2271, 10.1084/jem.20061308

Dinarello, 2006, IL-32, a novel cytokine with a possible role in disease, Ann Rheum Dis, 65, iii61

Kim, 2005, Interleukin-32: a cytokine and inducer of TNFα, Immunity, 22, 131

Joosten, 2006, IL-32, a proinflammatory cytokine in rheumatoid arthritis, Proc Natl Acad Sci USA, 103, 3298, 10.1073/pnas.0511233103

Shoda, 2006, Interactions between interleukin-32 and TNF-α contribute to the exacerbation of immune-inflammatory diseases, Arthritis Res Ther, 8, R166, 10.1186/ar2074

Fava, 2003, A role for the lymphotoxin/LIGHT axis in the pathogenesis of murine collagen-induced arthritis, J Immunol, 171, 115, 10.4049/jimmunol.171.1.115

Han, 2005, Blockade of lymphotoxin pathway exacerbates autoimmune arthritis by enhancing the Th1 response, Arthritis Rheum, 52, 3202, 10.1002/art.21341

Perper, 2006, TWEAK is a novel arthritogenic mediator, J Immunol, 177, 2610, 10.4049/jimmunol.177.4.2610

Taylor, 2000, Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis, Arthritis Rheum, 43, 38, 10.1002/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L

Paleolog, 1996, Deactivation of vascular endothelium by monoclonal antitumor necrosis factor alpha antibody in rheumatoid arthritis, Arthritis Rheum, 39, 1082, 10.1002/art.1780390703

Haringman, 2006, A randomized controlled trial with an anti-CCL2 (antimonocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis, Arthritis Rheum, 54, 2387, 10.1002/art.21975

Koch, 1992, Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis, J Clin Invest, 90, 772, 10.1172/JCI115950

Elliott, 1993, Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha, Arthritis Rheum, 36, 1681, 10.1002/art.1780361206